Syon Capital LLC Acquires 819 Shares of Boston Scientific Co. (NYSE:BSX)

Syon Capital LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 4.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,069 shares of the medical equipment provider’s stock after buying an additional 819 shares during the period. Syon Capital LLC’s holdings in Boston Scientific were worth $1,102,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. FMR LLC boosted its position in Boston Scientific by 6.8% during the 3rd quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after acquiring an additional 8,045,263 shares in the last quarter. American Century Companies Inc. lifted its position in Boston Scientific by 391.6% during the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock worth $172,752,000 after acquiring an additional 2,606,253 shares during the period. Wellington Management Group LLP raised its stake in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after buying an additional 2,336,348 shares during the last quarter. Winslow Capital Management LLC increased its stake in Boston Scientific by 39.3% during the 3rd quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider’s stock worth $323,641,000 after buying an additional 1,730,133 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after purchasing an additional 1,525,432 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

NYSE:BSX traded up $0.35 during midday trading on Thursday, reaching $73.26. The stock had a trading volume of 8,171,272 shares, compared to its average volume of 6,560,628. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The stock has a market capitalization of $107.48 billion, a P/E ratio of 68.46, a PEG ratio of 2.42 and a beta of 0.78. The firm’s fifty day simple moving average is $67.53 and its 200-day simple moving average is $60.28. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same period last year, the firm earned $0.45 EPS. On average, equities research analysts forecast that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. BTIG Research restated a “buy” rating and issued a $64.00 price objective on shares of Boston Scientific in a research note on Friday, December 29th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research note on Thursday. Royal Bank of Canada raised their price objective on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Evercore ISI increased their target price on shares of Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.00.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP John Bradley Sorenson sold 16,351 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,979 shares of company stock valued at $3,418,529. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.